StoxSai Life Sciences vs Wockhardt: share price & financials comparison
NSE: SAILIFE vs WOCKPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Sai Life Sciences vs Wockhardt at a glance
Sai Life Sciences (SAILIFE) has a market capitalisation of ₹40,972 Cr, against ₹32,841 Cr for Wockhardt (WOCKPHARMA). Over the past year Sai Life Sciences has returned +108.9%, compared with +48.5% for Wockhardt. On valuation, Wockhardt trades at a lower P/E of 80.1 versus 202.3. Wockhardt earns a higher return on equity (7.9% vs 7.5%). Sai Life Sciences comes out ahead on size, financial health, momentum and technicals. Wockhardt comes out ahead on valuation, profitability and growth. Across the scored metrics below, Sai Life Sciences leads on 7 and Wockhardt on 5. On StoxGud's 10-point checklist, Sai Life Sciences scores 6/10 and Wockhardt scores 6/10.
| Metric | Sai Life Sciences | Wockhardt |
|---|---|---|
| Size | ||
| Market cap | ₹40,972 Cr | ₹32,841 Cr |
| Revenue (latest FY) | ₹2,192 Cr | ₹3,373 Cr |
| Net profit (latest FY) | ₹349 Cr | ₹213 Cr |
| Valuation | ||
| P/E | 202.3 | 80.1 |
| P/B | 15.24 | 6.37 |
| Profitability | ||
| Return on equity | 7.5% | 7.9% |
| Net profit margin | 8.5% | 10.9% |
| Operating margin | 29.5% | 20.4% |
| Growth | ||
| Revenue growth (YoY) | +22.5% | +23.9% |
| Net profit growth (YoY) | — | +1.3% |
| Revenue CAGR (multi-year) | — | +4.5% |
| Financial health | ||
| Debt to equity | 0.17 | 0.42 |
| Momentum | ||
| 1-month return | +31.9% | +2.2% |
| 1-year return | +108.9% | +48.5% |
| 3-year CAGR | — | +92.3% |
| 5-year CAGR | — | +36.5% |
| 10-year CAGR | — | +11.2% |
| Distance from 52W high | +0.0% | -13.0% |
| Technicals | ||
| RSI (14) | 93 | 74 |
| Price vs 200-day avg | +56.3% | +17.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Sai Life Sciences | Wockhardt |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Sai Life Sciences or Wockhardt?
Sai Life Sciences has a market cap of ₹40,972 Cr and Wockhardt has a market cap of ₹32,841 Cr as of 13 Nov 2026.
Which has a lower P/E, Sai Life Sciences or Wockhardt?
Wockhardt has the lower P/E: Sai Life Sciences trades at 202.3 and Wockhardt at 80.1.
Which gave better returns in the last year, Sai Life Sciences or Wockhardt?
Sai Life Sciences did better: Sai Life Sciences returned +108.9% and Wockhardt returned +48.5% over one year.
What is the difference between Sai Life Sciences and Wockhardt?
Both are NSE-listed companies in Healthcare. Sai Life Sciences is about 1.2 times the size of Wockhardt by market cap. In the latest financial year Sai Life Sciences reported revenue of ₹2,192 Cr and Wockhardt ₹3,373 Cr. Operating margin is 29.5% for Sai Life Sciences and 20.4% for Wockhardt. Debt to equity is 0.17 for Sai Life Sciences and 0.42 for Wockhardt.
Which is better, Sai Life Sciences or Wockhardt?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Sai Life Sciences leads on 7 and Wockhardt on 5. Sai Life Sciences is ahead on size, financial health, momentum and technicals. Wockhardt is ahead on valuation, profitability and growth. On StoxGud's rules-based checklist Sai Life Sciences scores 6/10 and Wockhardt scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.